Security key
71715X203
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value per share (PMCB)
CUSIP: 71715X203
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 977,850
- Total 13F value
- $2,316,963
- Share change
- -110,227
- Put/Call ratio
- 7.4%
- SEC-reported price per share
- $2.37
- Number of holders
- 27
- Value change
- -$237,143
- Number of buys
- 9
- Number of sells
- 13
- Shares outstanding
- 10,666,413
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
27
Top holders
10
PMCB full security history
Ownership snapshot
Full 13F holder table
PharmaCyte Biotech, Inc. SEC filings
PharmaCyte Biotech, Inc. company facts
PharmaCyte Biotech, Inc. 13D/G history
Broader feeds
Ownership snapshot
Top reported holders of PMCB - PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
K2 PRINCIPAL FUND, L.P.
Disclosed value leader
K2 PRINCIPAL FUND, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2023
13F
Lead comparable stake: 2.9%
Showing 1-6 of 15 holder rows.
Quick read
K2 PRINCIPAL FUND, L.P. leads the comparable SEC ownership view at 2.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens K2 PRINCIPAL FUND, L.P.'s linked filing trail.
Comparable ownership
Top 5
K2 PRINCIPAL FUND, L.P.
2.9%
GEODE CAPITAL MANAGEMENT, LLC
2%
VANGUARD GROUP INC
1.6%
EQUITEC PROPRIETARY MARKETS, LLC
0.78%
SABBY MANAGEMENT, LLC
0.77%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| K2 PRINCIPAL FUND, L.P. |
13F
Company
|
2.9%
|
$654,918
304,613 shares
|
— | 31 Dec 2023 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2%
|
$465,801
215,637 shares
|
— | 31 Dec 2023 |
| VANGUARD GROUP INC |
13F
Company
|
1.6%
|
$370,084
171,335 shares
|
— | 31 Dec 2023 |
| EQUITEC PROPRIETARY MARKETS, LLC |
13F
Company
|
0.78%
|
$178,690
82,727 shares
|
— | 31 Dec 2023 |
| SABBY MANAGEMENT, LLC |
13F
Company
|
0.77%
|
$177,926
82,373 shares
|
— | 31 Dec 2023 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.36%
|
$82,000
38,100 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
27
Shares
977,850
Rows available
27
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
27
Q1 2024 holders
27
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|